Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
Japan officially kicked off its Upper House election campaign on July 3. The race draws special attention this year as it marks the first national election under the minority government of Prime Minister Shigeru Ishiba, with the outcome of the…
To read the full story
Related Article
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback
July 23, 2025
- Japan’s Ruling Bloc Routed in Upper House Poll; Takemi to Retire, Furukawa, Kamayachi, and Honda Secure Seats
July 22, 2025
- Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
July 14, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
- LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
REGULATORY
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
- Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…